Compare IPW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | BLRX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 12.6M |
| IPO Year | 2021 | 2010 |
| Metric | IPW | BLRX |
|---|---|---|
| Price | $1.39 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 96.3K | 13.0K |
| Earning Date | 05-14-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,142,779.00 | N/A |
| Revenue This Year | $149.67 | N/A |
| Revenue Next Year | $15.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $2.28 |
| 52 Week High | $29.10 | $7.77 |
| Indicator | IPW | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.17 | 32.44 |
| Support Level | $0.50 | N/A |
| Resistance Level | $2.79 | $3.93 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 0.34 | 0.00 |
iPower Inc is a United States-based online retailer and supplier of consumer home, pet, garden, outdoor, and consumer electronics products. It also operates as a provider of value-added ecommerce services for third-party products and brands. The company's capabilities include a spectrum of online channels, fulfillment capacity, a network of warehouses serving the U.S., last-mile delivery partners, and a differentiated business intelligence platform. The company's sales channels currently include Amazon Vendor, Amazon 3P, Walmart.com, TikTok, Temu, and other marketplaces, as well as its own e-commerce websites, such as simpledeluxe.com and more. Additionally, it is developing in-house branded products and through supply chain partners, which include iPower, Simple Deluxe, and other brands.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.